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Prescription opioids are a class of medications that are commonly prescribed for the relief of many kinds of pain syndromes. Although these medications have an important role in the management of pain, the misuse and abuse of these drugs has contributed to a still‐growing public health concern. According to data from the Centers for Disease Control and Prevention (CDC), the number of overdose deaths that involved the use of opioid medications (both illicit and prescription products) has increased sixfold from 1999 to 2017 \[[1](#onco13000-bib-0001){ref-type="ref"}\]. In response to this epidemic, the CDC has put forth many efforts to combat the devastating impact that opioid misuse and abuse has had on communities across the country. In March 2016, the CDC published guidelines for prescribing opioids for chronic pain, and these guidelines were the catalyst for change in many different practice settings \[[2](#onco13000-bib-0002){ref-type="ref"}\]. However, in February 2019, the CDC published a letter addressing concerns of the implications of the guideline on treating patients with cancer that were posed by the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the American Society of Hematology \[[3](#onco13000-bib-0003){ref-type="ref"}\]. This response letter clarifies that the guideline was intended to provide best practice recommendations for primary care clinicians who prescribe opioids for chronic pain outside of active cancer treatment, palliative care, and end‐of‐life care \[[3](#onco13000-bib-0003){ref-type="ref"}\]. It is important to realize that patients with cancer‐related pain have unique treatment needs compared with patients with other chronic, noncancer pain, which makes the translation of many different recommendations and risk reduction strategies more controversial in this exclusive patient population. However, no patient population is exempt from potential opioid misuse or opioid‐related harm; therefore, risk mitigation strategies should always be considered in the process of creating a comprehensive care plan. This article will focus on two specific harm‐reduction efforts, specifically, the use of abuse‐deterrent formulations of prescription opioids and the prescription of naloxone for those at increased risk of intentional or unintentional overdose, and their practical implications for use in patients with cancer pain.

Abuse‐Deterrent Technology {#onco13000-sec-0004}
==========================

The use of extended‐release (ER) or long‐acting (LA) opioid formulations is very common in clinical practice when treating patients with cancer pain that is not responsive to other, nonopioid analgesics. The use of ER or LA opioids for chronic cancer pain management results in significant benefits over the sole use of immediate‐release (IR) formulations, including reduction in overall baseline pain, improved sleep, and convenience of administration \[[4](#onco13000-bib-0004){ref-type="ref"}\]. The danger of manipulating ER or LA products for misuse, compared with that of IR products, is that there is often a greater amount of drug in each dosing unit, which greatly increases the risk of overdose when manipulated for misuse. However, this very reason is why the ER and LA formulations are of great value to those who seek to misuse opioids: a higher dose will likely result in a greater "high." The challenge health care providers are facing is how to balance the appropriate use of prescription opioids with the risks and consequences that are associated with potential misuse and abuse.

One mechanism that was developed to help mitigate the misuse of prescription opioids was abuse‐deterrent technology. Abuse‐deterrent technology is utilized with the intent of discouraging manipulation (e.g., crushing, snorting, injecting) of prescription products or making the use of the manipulated product less appealing \[[5](#onco13000-bib-0005){ref-type="ref"}\]. The result of using this technology as a method of regulating prescription drug misuse was the production abuse‐deterrent formulations (ADFs) of opioids \[[5](#onco13000-bib-0005){ref-type="ref"}\]. ADFs include all opioid products that have one or more properties that increase the difficulty of abuse, make abuse less attractive and/or less rewarding \[[1](#onco13000-bib-0001){ref-type="ref"}\], \[[4](#onco13000-bib-0004){ref-type="ref"}\]. Prior to the use of ADFs, all opioids were susceptible to physical manipulation meant to alter the routes of administration from their intended use \[[4](#onco13000-bib-0004){ref-type="ref"}\].

At first glance, these ADFs seem like a wonderful solution to reduce risk, abuse, and addiction. These products give providers a mechanism by which to effectively treat patients with chronic pain while limiting abuse, with the intention to then limit rates of addiction and substance use disorder. Unfortunately, it is not quite that simple. There are clear advantages but also significant limitations to the use of ADFs in clinical practice, and all should be considered carefully when evaluating their role.

Practical Advantages and Limitations to ADFs {#onco13000-sec-0005}
============================================

There are multiple mechanisms which by abuse‐deterrent technology is utilized. It is important to recognize that opioid products can be abused in multiple ways \[[1](#onco13000-bib-0001){ref-type="ref"}\]. Common routes of abuse include swallowing whole, crushing and swallowing, chewing and swallowing, crushing and snorting, crushing and smoking, and dissolving and injecting \[[1](#onco13000-bib-0001){ref-type="ref"}\], \[[4](#onco13000-bib-0004){ref-type="ref"}\]. The U.S. Food and Drug Administration (FDA) currently categorizes different ADF technology into groups including physical or chemical barriers, agonist‐antagonist combinations, aversion technology, delivery system technology, new molecular entities and prodrugs, combinations of these ADFs, and other novel approaches \[[1](#onco13000-bib-0001){ref-type="ref"}\]. More descriptive information about each of these categories can be found below. The intent of these technology categories is to reduce the likelihood that the product can be converted into a form that could be snorted or injected, thereby inhibiting some of the most frequently used routes of abuse.

Physical or chemical barriers \[[1](#onco13000-bib-0001){ref-type="ref"}\]:Physical barriers: prevent crushing, chewing, cutting, grating, or grinding of the dosage form.Chemical barriers: gelling agents that help resist extraction using common solvents like water, simulated biological media, alcohol, or other organic solvents.Physical and chemical barriers limit drug release following mechanical manipulation, or change the physical form of a drug, rendering it less amenable to abuse.

Agonist‐antagonist combinations \[[1](#onco13000-bib-0001){ref-type="ref"}\]:An opioid antagonist can be added to interfere with, reduce, or defeat the euphoria associated with abuse. The antagonist can be sequestered and released only upon manipulation of the product.For example, a drug product can be formulated such that the substance that acts as an antagonist is not clinically active when the product is swallowed but becomes active if the product is crushed and injected or snorted.

Aversion technology \[[1](#onco13000-bib-0001){ref-type="ref"}\]:Substances can be added to the product to produce an unpleasant effect if the dosage form is manipulated or is used at a higher dosage than directed.For example, the formulation can include a substance irritating to the nasal mucosa if ground and snorted.

Delivery system technology \[[1](#onco13000-bib-0001){ref-type="ref"}\]:Certain drug release designs or the method of drug delivery can offer resistance to abuse.For example, sustained‐release depot injectable formulation or a subcutaneous implant may be more difficult to manipulate.

Combinations \[[1](#onco13000-bib-0001){ref-type="ref"}\] of these technologies refers to the use of two or more of the above‐mentioned methods combined to deter abuse. And the category of novel approaches \[[1](#onco13000-bib-0001){ref-type="ref"}\] encompasses any means or technologies that are not captured in the previous categories.

The use of these ADF technologies was shown in clinical studies to demonstrate significant reduction in various abuse‐related parameters and indicators \[[6](#onco13000-bib-0006){ref-type="ref"}\], as well as a decrease in intentional and unintentional overdose events \[[6](#onco13000-bib-0006){ref-type="ref"}\]. What is important to remember is that many of these studies look at abuse of a single product or two products at most. What these studies have failed to depict is that the reduction in abuse of a single product does not carry across the entire class of opioid medications. A study by Cicero and colleagues showed that use of Oxycontin as a primary drug of abuse decreased from 35.6% to 12.8% in 21 months following its release as an ADF product, but simultaneously, the abuse of hydrocodone and other oxycodone products increased slightly, and the abuse of high‐potency fentanyl and hydromorphone rose markedly, from 20.1% to 32.3% over the same time frame \[[7](#onco13000-bib-0007){ref-type="ref"}\]. This study also demonstrated that of all opioids used to "get high in the past 30 days at least once," Oxycontin fell from 47.7% to 30.0%, whereas heroin rates nearly doubled \[[7](#onco13000-bib-0007){ref-type="ref"}\].

It is fair to say that the literature regarding the use of ADFs can be slightly misleading when looking at single studies. The intended decrease in abuse of prescription opioids was not demonstrated to occur across the entire class of prescription opioids but rather was limited to specific abuse rates of individual products, such as Oxycontin. Additionally, there are other limitations of ADFs that are important to highlight.

As new ADFs are brought to market, they are available first as branded products and are markedly more expensive than the generic, non‐abuse‐deterrent formulations that are currently on the market \[[6](#onco13000-bib-0006){ref-type="ref"}\]. This can be a barrier for patients without insurance, but also for those with insurance, as companies are hesitant to spend more money on a drug that is available more cheaply. However, as more third‐party payers include ADFs in covered formularies, patients may not have to pay as much out of pocket for these medications \[[6](#onco13000-bib-0006){ref-type="ref"}\].

It is also important to understand that ADF technology simply implies that a drug product is abuse deterrent, but it does not mean abuse‐proof. Although the intent of ADF technology is to limit the abuse potential, there is a caveat with all ADF products brought to market that abuse is still possible. No ADF product on the market can prevent abuse or misuse by simply swallowing more than the prescribed number of dose units. The use of ADF technology alone is not enough to cease all abuse of prescription opioids, which is a deeply rooted concern across the U.S. More importantly, an opioid that is produced with ADF technology does not make the drug product any less addictive, which is a common misconception by many users. Misuse of ADF opioids can result in addiction in the same way that non‐ADF opioids can, and they should not be considered a "safer" alternative to generic opioids. Although there are many commercially available products that use abuse‐deterrent technology, only eight of those products have received FDA abuse‐deterrent labeling. A comprehensive list of the commercially available, FDA‐approved products with abuse‐deterrent labeling, the available formulation, and their specific abuse‐deterrent mechanism can be found in Table [1](#onco13000-tbl-0001){ref-type="table"}.

###### Commercially available products that have U.S. Food and Drug Administration‐approved labeling describing abuse‐deterrent properties using ADF technology
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Abbreviations: ADF, abuse‐deterrent formulation; ER, extended release; IR, immediate release.

Naloxone: Risk Mitigation Strategy {#onco13000-sec-0006}
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An alternative method of risk mitigation related to the opioid crisis is providing the use of naloxone for the reversal of intentional as well as unintentional opioid overdose. Numerous societies and guidelines have adapted to advocate for naloxone to be used as a harm‐reduction strategy \[[8](#onco13000-bib-0008){ref-type="ref"}\] for patients with a history of opioid use disorder as well as those on prescription opioids for pain management. The increasing rate of opioid‐related overdose deaths has led to the increasing use of naloxone in the community \[[8](#onco13000-bib-0008){ref-type="ref"}\]. Naloxone is available in different routes of administration, including intravenous, intramuscular, and intranasal, with growing popularity of the intranasal formulation in the community.

Naloxone use in the setting of opioid overdose reversal is a relatively safe and effective treatment. The most notable adverse effect of naloxone use is the precipitation of severe opioid withdrawal \[[9](#onco13000-bib-0009){ref-type="ref"}\]. Abrupt reversal of opioid effects in a person who is physically dependent on opioids has been shown to precipitate acute withdrawal syndrome which includes symptoms such as body aches, fever, sweating, runny nose, piloerection, weakness, shivering, nervousness, restlessness, diarrhea, nausea and vomiting, abdominal cramps, increased blood pressure, and tachycardia \[[9](#onco13000-bib-0009){ref-type="ref"}\].

Controversy of Naloxone Use in Patients with Cancer {#onco13000-sec-0007}
===================================================

Although the use of naloxone as a means of harm‐reduction for those at high risk of overdose has been well studied and widely accepted, there is some controversy surrounding the use of naloxone in patients who have life‐limiting illnesses, including cancer. Patients who are diagnosed with a life‐limiting condition pose a very specific challenge for health care providers to balance the risks and benefits of opioid use for symptom management. An important question to address in this patient population is, Are the risk mitigation strategies used in the general population easily translatable to those who have a life‐limiting disease? The answer may not be as clear as one would hope.

Pain is one of the most common symptoms associated with a cancer diagnosis and can have negative impact on a person\'s functional status and quality of life \[[10](#onco13000-bib-0010){ref-type="ref"}\]. Pain occurs in 20% to 50% of patients with cancer, and roughly 80% of patients with advanced‐stage cancer have moderate to severe pain \[[10](#onco13000-bib-0010){ref-type="ref"}\]. Additionally, the use of opioid medications for the relief of moderate to severe cancer pain is considered necessary for most patients at some point during the disease process \[[10](#onco13000-bib-0010){ref-type="ref"}\]. Patients with cancer pain can be on opioid medications for long periods of time, and their medications are often titrated to significant doses because of tolerance that builds over time. Patients with cancer pain who are on high‐dose opioids are considered a high‐risk population for opioid overdose, so it stands to reason that utilization of risk mitigation strategies, such as naloxone prescribing, is appropriate. In many clinic settings, this thought process is followed consistently for patients on opioids for cancer pain who have good functional status and good overall quality of life. The implementation of naloxone prescribing in this subpopulation is likely to have greater benefits than risks in the setting of suspected opioid intoxication. The controversy arises when discussing patients with short prognosis, poor functional status, and high symptom burden.

One immediate concern of prescribing naloxone to patients with a diagnosis of terminal, end‐stage cancer is that the signs and symptoms that present with imminent death are very difficult to distinguish from opioid intoxication, even for highly trained health care professionals. Providers and other trained medical professionals can use their knowledge of the pharmacokinetics and pharmacodynamics of a given drug along with an in‐depth assessment of patient\'s decline to try to distinguish between these two processes. However, a concern of palliative care and hospice providers is that family members and caregivers of patients who reside at home, may be imminently dying, and are on opioid therapy for symptom control, will not be able to distinguish between the two states. The negative outcomes that may result if naloxone is given inappropriately include physical and emotional suffering of the patient, as well as emotional suffering of the caregiver who administered the medication. The implementation of naloxone prescribing in this subpopulation of patients is likely to have much greater risk or harm than benefit in the setting of suspected opioid intoxication because of reasons discussed above.

The other setting in which naloxone can be beneficial to prescribe to patients with cancer pain is if there is a history of or risk of abuse of the patient\'s medications by a family member or friend who is frequently in the home or has access to the medications. Although it may be controversial to utilize naloxone on a patient battling cancer, there is more evidence for use in someone without a serious illness, who misuses opioids with no therapeutic indication and experiences an intentional or unintentional overdose. The presence of opioid medications in the home increases the risk of misuse, abuse, or overdose by family members and friends simply because of access. The patient and prescriber should explore prescribing naloxone for this specific purpose after determining the potential for harm on a case‐by‐case basis.

**For Further Reading:** Judith A. Paice. Risk Assessment and Monitoring of Patients with Cancer Receiving Opioid Therapy. ***The Oncologist*** 2019;24:1294--1298; first published on May 22, 2019.

**Implications for Practice:** Throughout the trajectory of cancer care, opioid use is often indicated, and, in fact, it may be unethical to limit or prohibit the use of opioids when pain is severe. Oncologists face the significant challenge of providing cancer pain control that is safe and effective, while limiting individual risk for abuse or overdose and keeping the community free of diverted substances. Most oncology providers report inadequate training in chronic pain principles and in managing addiction. Risk assessment and mitigation measures can be incorporated within oncology care to enhance effective pain management while reducing the potential for harm.
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